Some drugs containing valsartan recalled due to potential carcinogen

Some drugs containing valsartan recalled due to potential carcinogen

The drugs, made with the active ingredient valsartan, were found to contain N-nitrosodimethylamine (NDMA), a chemical that's been classified as a probable human carcinogen by the International Agency for Research on Cancer.

Valsartan, a drug widely used to control blood pressure is being recalled in several countries around the world because of its chemical ingredient possibly linking to cancer.

Only some valsartan medicines in the European Union are affected and these are being recalled.

"People taking valsartan medication affected by this recall are advised to not stop taking their medication, but to speak to their doctor or healthcare professional who can advise on alternative treatment", asserted Dr Sam Atkinson, MHRA's director of the Inspection, Enforcement and Standards Division. The recall was issued after the Ministry's senior officials reviewed Ministerial Resolution No. (366) of 2010 governing the withdrawal, suspension, or prevention of distribution of pharmaceutical and medical products to protect public health.

US warns of sanctions risk for firms invested in Russian pipeline
It's a awful mistake. "We consider this to be a manifestation of unfair competition", Peskov said, adding that U.S. Vice-President of the European Commission for Energy Union Maros Sefcovic has informed the U.S.

The agency listed 28 impacted products containing valsartan being recalled by their manufacturers. The recall order was sent to authorized agents and distributors of the recalled products with an order to quarantine all quantities of the products present within their warehouses.

Valsartan is used to treat hypertension and can prevent cardiovascular complications associated with the condition. "This active substance is used in a number of medicines marketed in Europe".

EMA and United Kingdom regulators are working together to investigate the extent of the issues and any possible impact for patients. The CHMP opinion will then be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU member states.

Related Articles